A lthough chronic obstructive pulmonary disease (COPD) and restrictive lung diseases are important causes of morbidity and mortality in the United States (1-3), a large proportion of the morbidity and mortality is not pulmonary (4) . This raises the possibility that lung disease may be an indicator of susceptibility to the development of other diseases or may be associated with systemic inflammation that leads to other diseases (5, 6) . Previous analyses of the relation between lung function and markers of inflammation (7, 8) have not looked at restrictive lung disease separately.
We applied spirometric criteria to define obstructive and restrictive lung disease in adults who had pulmonary function measurements obtained as part of the Third National Health and Nutrition Examination Survey (NHANES III). We then assessed the relation of impaired lung function to circulating levels of C-reactive protein and fibrinogen, adjusting for potential covariates that may also influence these measures.
METHODS

Study Sample
NHANES III was conducted from 1988 to 1994 by the National Center for Health Statistics of the Centers for Disease Control and Prevention, Atlanta, Georgia (9). Our study sample was limited to 15,697 adults aged 17 years or older who had undergone pulmonary function testing either at home or at the mobile examination center, and had complete data on their race, smoking status, height, and presence of respiratory symptoms. Serum and plasma samples were obtained during the examination. Fibrinogen levels were available on 8342 adults aged Ն40 years.
Definition of Variables
Race was classified as white, black, Mexican American, or other, and was determined by self-report on the questionnaire. Other demographic variables included sex, education (Ͻ12 years, 12 years, or Ն13 years), and age. We defined subjects as being current, former, or never smokers, based on their responses to series of questions. Current pipe or cigar smokers were considered current smokers. We calculated pack-years of cigarette use by multiplying the average number of cigarettes smoked daily by the number of years smoked and dividing the product by 20.
We classified subjects as having a respiratory symptom if they gave a positive response to questions involving specific symptoms of cough, phlegm, wheeze, or dyspnea. Subjects were asked whether they had an upper respiratory or lower respiratory illness recently. We classified subjects as having or not having cardiovascular disease (physician diagnosis of stroke, myocardial infarction, or heart failure), diabetes mellitus (physician-diagnosed), or chronic inflammatory rheumatic disease (physician diagnosis of systemic lupus erythematosus or rheumatoid arthritis). Body mass index, which was calculated by dividing the weight (kg) by height (m 2 ), was divided into four strata: Ͻ18.5 kg/m 2 , Ն18. 
Laboratory Measurements
C-reactive protein levels were measured using latex-enhanced nephelometry (13). The limit of detection for this assay was 3.0 mg/L; subjects with undetectable levels were assigned a level of 2.1 mg/L (3.0/1.41). Fibrinogen levels were measured using immunochemical methods on people aged Ն40 years (13). levels and Ն10.0 mg/L to define "highly elevated" levels in categorical analyses (14) . Linear and logistic regression models were adjusted for age, race, sex, education level, smoking status, body mass index, and the presence of cardiovascular disease, diabetes mellitus, or inflammatory rheumatic disease. We exponentiated results from the log-transformed regression models to yield a percentage increase (from the reference value) for the outcome. For analyses, we used both SAS and SUDAAN, a program that adjusts for the complex sample design when calculating variance estimates (15, 16) .
RESULTS
Our final data set included 15,697 subjects, representing an estimated 170 million adults in the United States. The pulmonary function criteria classified 2% of subjects as having severe COPD, 5% as having moderate COPD, and 6% as having restrictive lung disease (Table 1) . Compared with subjects who had no lung disease, fibrinogen and C-reactive protein levels were elevated in those with any measure of lung disease, as were the proportions of those with C-reactive protein levels Ն3.0 mg/L or Ն10.0 mg/L (Table 2) .
After adjustment for age, sex, race, smoking status, pack-years of smoking, body mass index, and the presence of chronic disease, every measure of lung disease, except mild COPD and respiratory symptoms, was associated with higher levels of fibrinogen and C-reactive protein, and with C-reactive protein levels Ն3.0 mg/L or Ն10.0 mg/L ( Table 3) . The effect of current or former smoking on C-reactive protein levels was less than that seen with moderate or severe COPD or restrictive lung disease.
When stratified by smoking status and lung function level, the proportion of participants with a C-reactive protein level Ն10 mg/L was increased in subjects with lung function impairment compared with in subjects who had no lung disease (Figure) .
DISCUSSION
In this analysis of a nationally representative sample of 15,697 U.S. adults, both obstructive and restrictive lung diseases were predictors of increased levels of plasma fibrinogen and serum C-reactive protein. This association remained significant after adjusting for several covariates related to fibrinogen, C-reactive protein, and lung function.
Patients with COPD have an increased risk of cardiovascular disease. The explanation for this association is unknown, but thought to be related to some of the factors associated with obstructive lung disease, such as smoking, chronic infection, or cor pulmonale (17) (18) (19) . Recent work has focused on the systemic and inflammatory nature of COPD, such as its association with a catabolic state and chronic muscle wasting (20 -22) . The association be- tween elevated C-reactive protein and fibrinogen levels and cardiovascular disease has been well established (23, 24) . Thus, our findings provide a potential mechanism for the association between impaired lung function and cardiovascular health. Whereas previous research has demonstrated an association between emphysema (25), chronic bronchitis (8), or FEV 1 (7) and C-reactive protein levels, this analysis used the new criteria of the Global Initiative for COPD to define categories of impaired lung function (12) . A new finding in this analysis was the association of restrictive lung disease with elevated C-reactive protein and fibrinogen levels. Many pathologic mechanismsranging from obesity to interstitial lung disease to spaceoccupying lesions (2,26)-can cause restrictive lung disease. Inflammation is an important pathway for several different causes of restrictive lung disease, such as sarcoidosis or idiopathic pulmonary fibrosis (27) . In addition, respiratory infections can also result in restrictive spirometric values.
C-reactive protein is mainly synthesized in hepatocytes, although it is also synthesized in lymphocytes and alveolar macrophages (28 -30) . C-reactive protein levels can also increase in response to an acute infection (31), but chronic infections such as periodontitis can also increase these inflammatory markers (32) .
Fibrinogen is also an acute phase reactant that has been linked to cardiovascular disease (33) . It is synthesized in the liver, and increased serum levels are related to both higher synthesis and lower degradation rates (34, 35) . In our analysis, the increase in fibrinogen levels related to impaired lung function was less than the increase in Creactive protein levels (Table 3) .
This analysis is subject to several limitations. Because this was a cross-sectional study, we cannot say that lung function abnormality results in increased C-reactive pro- 
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tein or fibrinogen levels. An alternative explanation might be that systemic inflammatory processes could result in impaired lung function. Another limitation is that the assay for C-reactive protein that we used had a limit of detection of 3 mg/L, and there is evidence of cardiovascular risk at levels below 3 mg/L (36).
In conclusion, our data demonstrate an association between both obstructive and restrictive lung disease and elevated levels of fibrinogen and C-reactive protein. This finding provides additional data linking respiratory disease to adverse outcomes outside of the pulmonary system.
